EL PFDD with Japanese Subtitles скачать в хорошем качестве

EL PFDD with Japanese Subtitles

The National Ataxia Foundation and CureDRPLA jointly held an externally-led patient focused drug development meeting on September 25, 2020 for Polyglutamine Spinocerabellar Ataxias (SCA1, SCA2, SCA3, SCA6, SCA7, SCA8, SCA17) and Dentatorubral-Pallidoluysian Atrophy, more commonly referred to as SCAs and DRPLA, respectively. The purpose of the meeting was to create a forum where patients and caregivers could describe their experiences with the diseases and convey what would be most important to them to see in a treatment. The meeting was attended by members of the FDA, researchers, scientists, academics and industry. A Voice of the Patient report will be publicly available in early 2021 to communicate the key meeting takeaways. Meeting sponsors were Biohaven Pharmaceuticals, Ionis, Takeda, uniQure, and Vico Therapeutics.